Literature DB >> 10991839

CD4(+)-T-Cell-mediated resistance to systemic murine candidiasis induced by a membrane fraction of Candida albicans.

S Mizutani1, M Endo, T Ino-Ue, M Kurasawa, Y Uno, H Saito, K Onogi, I Kato, K Takesako.   

Abstract

We induced resistance to systemic Candida albicans infection through CD4(+)-cell-mediated immunity in mice by immunization with subcutaneous injections of live C. albicans cells emulsified in incomplete Freund adjuvant. Using the resistant mice, we tested subcellular fractions of C. albicans cells for antigenicity. The fractions were derived from digested surface cell walls, insoluble membranes, or soluble and insoluble cytoplasmic materials, which were prepared by treatment with cell wall-digesting enzymes followed by lysis of the consequent protoplasts. Interestingly, the live-cell-immunized mice showed strong cell-mediated immune responses to the membrane fraction (C. albicans membrane antigen [CMA]). In addition, immunization with CMA induced resistance to systemic candidiasis, which disappeared upon administration of anti-CD4 monoclonal antibody. Infusion of splenocytes from the CMA-immunized mice conferred resistance on SCID mice, whereas infusion of CD4(+)-T-cell-depleted splenocytes was unable to induce resistance, indicating the importance of CD4(+) lymphocytes for resistance. These results suggest a potential for the membrane fraction to act as an antigen conferring resistance to systemic candidiasis in place of live cells and also as a source for the isolation of a new antigen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991839      PMCID: PMC90130          DOI: 10.1128/AAC.44.10.2653-2658.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice.

Authors:  E Cenci; L Romani; A Vecchiarelli; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

2.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Immunity to Candida albicans.

Authors:  T J Rogers; E Balish
Journal:  Microbiol Rev       Date:  1980-12

4.  Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions.

Authors:  L Scaringi; P Marconi; M Boccanera; L Tissi; F Bistoni; A Cassone
Journal:  J Gen Microbiol       Date:  1988-05

5.  A cell surface/plasma membrane antigen of Candida albicans.

Authors:  R K Li; J E Cutler
Journal:  J Gen Microbiol       Date:  1991-03

6.  Lymphoproliferative and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans.

Authors:  A Torosantucci; C Palma; M Boccanera; C M Ausiello; G C Spagnoli; A Cassone
Journal:  J Gen Microbiol       Date:  1990-11

7.  Candidiasis in the transplant patient.

Authors:  R A Clift
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

8.  Systemic candidiasis in mice immunized with Candida albicans ribosomes.

Authors:  R Levy; E Segal; L Barr-Nea
Journal:  Mycopathologia       Date:  1985-07       Impact factor: 2.574

9.  T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice.

Authors:  E Cenci; L Romani; A Vecchiarelli; P Puccetti; F Bistoni
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

10.  Immune responses elicited by vaccinations with Candida albicans ribosomes in cyclophosphamide treated animals.

Authors:  E Segal; H Sandovsky-Losica; S Nussbaum
Journal:  Mycopathologia       Date:  1985-02       Impact factor: 2.574

View more
  4 in total

1.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

2.  Utilization of Hybrid Assembly Approach to Determine the Genome of an Opportunistic Pathogenic Fungus, Candida albicans TIMM 1768.

Authors:  Suresh Panthee; Hiroshi Hamamoto; Sanae A Ishijima; Atmika Paudel; Kazuhisa Sekimizu
Journal:  Genome Biol Evol       Date:  2018-08-01       Impact factor: 3.416

Review 3.  Candidiasis--do we need to fight or to tolerate the Candida fungus?

Authors:  M Raska; J Bĕláková; M Krupka; E Weigl
Journal:  Folia Microbiol (Praha)       Date:  2007       Impact factor: 2.629

4.  Cell Wall Polysaccharides of Candida albicans Induce Mast Cell Degranulation in the Gut.

Authors:  Atsuko Sakurai; Natsu Yamaguchi; Kei Sonoyama
Journal:  Biosci Microbiota Food Health       Date:  2012-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.